Avinza® - 24-h sustained-release oral morphine therapy

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 469-472

  Caldwell, Jacques R ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

Administration; Aged; Avinza; Morphine; Osteoarthritis; Pain

Indexed keywords

CIMETIDINE; FUMARIC ACID; MONOAMINE OXIDASE INHIBITOR; MORPHELAN; MORPHINE SULFATE; OPIATE; OXYCODONE; POLYMER; TALC; MORPHINE;

ANALGESIA; APNEA; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CHRONIC PAIN; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG COMPLICATION; MOOD DISORDER; MUSCLE TWITCH; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; OSTEOARTHRITIS; SIDE EFFECT; SLEEP; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; TREATMENT FAILURE; VOMITING; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN; REVIEW;

ADMINISTRATION, ORAL; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; MORPHINE; MULTICENTER STUDIES; PAIN;

EID: 85047692640     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.469     Document Type: Article

References (10)

1. ELIOT L, LOEWEN G, BUTLER J et al.: Steady-state pharmacokinetic comparison of a new, once-daily, extended-release morphine sulfate formulation and immediate-release morphine oral solution in healthy male subjects. 17th Annual Meeting of the American Academy of Pain Medicine, Miami Beach, Florida, USA (February 14-18 (2000) (Abstract 205).
2. PORTENOY R, SCIBERRAS A, ELIOT L et al.: Steady-state pharmacokinetic comparison of a new extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate to severe pain. J. Pain Symptom Manage. (2002) 23:292-300.
3. ELIOT L, GEISER R, LOEWEN G: Steady-state pharmacokinetic comparison of a new, once-daily extended-release morphine formulation (Morphelan™) and Oxycontin® twice daily. J. Oncol. Pharm. Pract. (2001) 7(1):1-8.
4. ELIOT L, CATO A, GEISER R, LOEWEN G: Evaluation of two loading-dose regimens of Morphelan® in healthy volunteers. J. Applied Res. (2002) 2:1-10.
5. ELIOT L, LOEWEN G, BUTLER J et al.: "Sprinkle dosine" of a new, once-a-day oral morphine extended-release formulation, Morphelan™ ROER™. Proceedings of the American Society of Clinical Oncology, San Francisco, California, USA (May 12-15 2001).
6. DOUGLAS MD, GARLAND WT, KELLY JB et al.: Efficacy of a new, once-daily rapid-onset, extended-release morphine formulation (Morphelan™ ROER™) and a twice-daily morphine sulfate controlled-release formulation (MS Contin®) in patients with chronic, moderate to severe pain. 20th Annual Scientific Meeting of the American Pain Society. Phoenix, Arizona, USA (April 19-22 2001) (Abstract 780).
7. WYNN D, RAUCK R, COOK D et al.: Long-term, open-label safety and efficacy evaluation of a new, oral, once-daily, extended-release morphine sulfate formulation (Avinza™, formerly known as Morphelan™). International Association for the Study of Pain, 10th World Congress on Pain, San Diego, USA (August 17-22 2002).
8. CALDWELL JR, RAPOPORT RJ, DAVIS JC et al.: Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J. Pain Symptom Manage. (2002) 23:278-291.
9. CALDWELL JR, DAVIS JC, OFFENBERG HL et al.: Efficacy of a new, once-daily, rapid-onset, extended-release morphine formulation and twice-daily MS Contin® on steep variables in patients with chronic, moderate-to-severe osteoarthritis pain. 2nd World Congress of World Institutes of Pain, Istanbul, Turkey June 27-30 (2001) (Abstract PTR10).
10. LIGAND PHARMACEUTICALS. Unpublished data.